Cambridge, MA — 12/02/2025 — Insilico Medicine (“Insilico”), a global leader in AI-powered drug discovery, and Atossa Therapeutics (“Atossa”) (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel treatments for breast cancer and other serious conditions, announce the publication of a joint study evaluating the potential of (Z)-endoxifen for glioblastoma multiforme (GBM). The peer-reviewed article, now published in Nature’s Scientific Reports, represents one of the most comprehensive AI-enabled analyses to date exploring whether endoxifen, an active metabolite of tamoxifen with known activity in endocrine-resistant breast cancer, may offer new therapeutic opportunities for one of the deadliest malignant brain tumors in adults. The study aimed to identify new oncology indications with high therapeutic potential for endoxifen, as monotherapy or in combination, by applying Insilico’s AI-powered PandaOmics platform across a wide range of cancer types based on its mechanisms of action. Through this systematic evaluation, GBM emerged as a top candidate for further investigation.

Hebrew University of Jerusalem is proud to announce that Prof. Moran Yassour, a leading researcher at the Faculty of Medicine and the School of Computer Science and Engineering, has been selected as one of the 2025 EMBO Young Investigators. She receives this prestigious recognition for her innovative research on the developing infant microbiome and its impact on pediatric health.

Researchers from Korea University Ansan Hospital and collaborators report that patients with restless legs syndrome (RLS) face a higher risk of developing Parkinson’s disease (PD). In a nationwide cohort of nearly 20,000 people, untreated RLS patients showed approximately double the PD incidence, while dopamine agonist treatment appeared to have a protective effect. The findings highlight the importance of early screening and effective RLS management to support long-term brain health.